Faruk Uguz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Faruk Uguz has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
Kazim Gezginc
Department of Obstetrics and Gynecology, University of Necmettin Erbakan, Meram Faculty of Medicine, Konya, Turkey
12 shared publicationsMine Sahingoz
7 shared publicationsFatih Kayhan
Department of Psychiatry, Faculty of Medicine, Mevlana University, Konya, Turkey
5 shared publicationsSemra Aydogan
University of Necmettin Erbakan, Meram Faculty of Medicine Konya, Turkey
5 shared publicationsEda Yakut
University of Health Sciences, Konya Training, Research Hospitals, Turkey
4 shared publications- Kazım Gezginç
Division of Perinatology, Department of Obstetrics and Gynecology, Medical School of Meram, Necmettin Erbakan University, 42200 Konya, Turkey
4 shared publications
Latest Publications
- 13 August 2025
- Published by Springer Nature
- p. 95-107
Obsessive–Compulsive Disorder and Repetitive Negative Thinking During the Postpartum Period
- 13 August 2025
- Published by Springer Nature
- p. 95-107
Obsessive–Compulsive Disorder and Repetitive Negative Thinking During the Postpartum Period
- 28 October 2024
- Published by Taylor & Francis in Health Care for Women International
- Vol. 46 (5) , 585-591
Treatment of women with generalized anxiety disorder during the postpartum period with paroxetine: A retrospective analysis of 11 years of clinical data
We presented the results on the efficacy of paroxetine in postpartum women with generalized anxiety disorder (GAD) in current study. We included data on 33 patients to our study retrospectively. The patients were evaluated using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition, the Clinical Global Impression-Improvement Scale, the Hamilton Depression rating Scale (HAM-D) and the Hamilton Rating Scale for Anxiety (HAM-A). The patients had significant improvement in both HAM-D and HAM-A scores following paroxetine treatment for 8 wk. The response and remission rates were 78.8 and 63.6%, respectively. Both rates were significantly higher the subgroup of patients without comorbid depression compared to patients with comorbid depression. Based on the findings of the present study, we suggest that paroxetine may be beneficial for in postpartum women with GAD.
- 28 October 2024
- Published by Taylor & Francis in Health Care for Women International
- Vol. 46 (5) , 585-591
Treatment of women with generalized anxiety disorder during the postpartum period with paroxetine: A retrospective analysis of 11 years of clinical data
We presented the results on the efficacy of paroxetine in postpartum women with generalized anxiety disorder (GAD) in current study. We included data on 33 patients to our study retrospectively. The patients were evaluated using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition, the Clinical Global Impression-Improvement Scale, the Hamilton Depression rating Scale (HAM-D) and the Hamilton Rating Scale for Anxiety (HAM-A). The patients had significant improvement in both HAM-D and HAM-A scores following paroxetine treatment for 8 wk. The response and remission rates were 78.8 and 63.6%, respectively. Both rates were significantly higher the subgroup of patients without comorbid depression compared to patients with comorbid depression. Based on the findings of the present study, we suggest that paroxetine may be beneficial for in postpartum women with GAD.
- 1 September 2023
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 43 (5) , 434-452
Prophylactic Management of Women With Bipolar Disorder During Pregnancy and the Perinatal Period
Many women with bipolar disorder experience episodes of illness or relapses over the perinatal period, especially in the immediate postpartum period. Risks associated with treated/untreated psychopathologies and fetal exposure to bipolar medications make the management of bipolar disorder during these periods challenging for clinicians and patients. In light of the available effectiveness and reproductive safety data, the current clinical update based on the opinions of a group of international perinatal psychiatry authors recommends general considerations and specific management strategies for each possible clinical scenario, including mixed features, predominant polarity, diagnosis of subtypes of bipolar disorder, severity of previous episodes, and risk of recurrence of mood episodes.
- 1 September 2023
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 43 (5) , 434-452
Prophylactic Management of Women With Bipolar Disorder During Pregnancy and the Perinatal Period
Many women with bipolar disorder experience episodes of illness or relapses over the perinatal period, especially in the immediate postpartum period. Risks associated with treated/untreated psychopathologies and fetal exposure to bipolar medications make the management of bipolar disorder during these periods challenging for clinicians and patients. In light of the available effectiveness and reproductive safety data, the current clinical update based on the opinions of a group of international perinatal psychiatry authors recommends general considerations and specific management strategies for each possible clinical scenario, including mixed features, predominant polarity, diagnosis of subtypes of bipolar disorder, severity of previous episodes, and risk of recurrence of mood episodes.
- 20 January 2022
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 155, 110725
Is there a higher prevalence of mood and anxiety disorders among pregnant women during the COVID-19 pandemic? A comparative study
- 20 January 2022
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 155, 110725
Is there a higher prevalence of mood and anxiety disorders among pregnant women during the COVID-19 pandemic? A comparative study
- Open Access
- 1 December 2021
- Published by EDITORA SCIENTIFIC in Brazilian Journal of Psychiatry
- Vol. 43 (6) , 617-620
Olanzapine and quetiapine in the prevention of a new mood episode in women with bipolar disorder during the postpartum period: a retrospective cohort study
Objective: To examine whether olanzapine and quetiapine are useful in the prevention of a new mood episode during the postpartum period. Methods: Data on 23 patients (n=14 for olanzapine and n=9 for quetiapine) with bipolar disorder who met the criteria for this study were retrospectively gathered. The diagnosis of bipolar disorder was determined by means of the DSM-IV. Results: The mean follow-up period was 33.95±12.07 weeks. Six (26.1%) of 23 patients experienced recurrent mood episodes during the postpartum period. Four of these six patients were taking olanzapine and two were taking quetiapine. Patients with recurrent mood episodes had a significantly stronger family history of bipolar disorder, higher number of past episodes, and earlier onset and longer duration of illness compared to patients without recurrent mood episodes. Conclusion: Monotherapy with olanzapine or quetiapine can be considered as an alternative to mood stabilizers in preventing the development of new mood episodes after childbirth.
- 1 December 2021
- Published by EDITORA SCIENTIFIC in Brazilian Journal of Psychiatry
- Vol. 43 (6) , 617-620
Open AccessOlanzapine and quetiapine in the prevention of a new mood episode in women with bipolar disorder during the postpartum period: a retrospective cohort study
Objective: To examine whether olanzapine and quetiapine are useful in the prevention of a new mood episode during the postpartum period. Methods: Data on 23 patients (n=14 for olanzapine and n=9 for quetiapine) with bipolar disorder who met the criteria for this study were retrospectively gathered. The diagnosis of bipolar disorder was determined by means of the DSM-IV. Results: The mean follow-up period was 33.95±12.07 weeks. Six (26.1%) of 23 patients experienced recurrent mood episodes during the postpartum period. Four of these six patients were taking olanzapine and two were taking quetiapine. Patients with recurrent mood episodes had a significantly stronger family history of bipolar disorder, higher number of past episodes, and earlier onset and longer duration of illness compared to patients without recurrent mood episodes. Conclusion: Monotherapy with olanzapine or quetiapine can be considered as an alternative to mood stabilizers in preventing the development of new mood episodes after childbirth.
- Open Access
- 1 September 2021
- Published by IMR Press in ALPHA PSYCHIATRY
- Vol. 22 (5) , 224-229
The Relationship Between Maternal Antidepressants and Neonatal Hypoglycemia: A Systematic Review
Antidepressive agents,hypoglycemia,pregnancy,therapeutics
- 1 September 2021
- Published by IMR Press in ALPHA PSYCHIATRY
- Vol. 22 (5) , 224-229
Open AccessThe Relationship Between Maternal Antidepressants and Neonatal Hypoglycemia: A Systematic Review
Antidepressive agents,hypoglycemia,pregnancy,therapeutics
- Open Access
- 12 April 2021
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 31 (1) , 1-8
The Role of the Central and the Peripheral Neuropeptides in Weight Gain and Metabolic Changes Related to Olanzapine
Neuropeptide,olanzapine,weight gain
- 12 April 2021
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 31 (1) , 1-8
Open AccessThe Role of the Central and the Peripheral Neuropeptides in Weight Gain and Metabolic Changes Related to Olanzapine
Neuropeptide,olanzapine,weight gain
- Open Access
- 1 February 2021
- Published by EDITORA SCIENTIFIC in Brazilian Journal of Psychiatry
- Vol. 43 (1) , 61-64
Cognitive-behavioral therapy in pregnant women with generalized anxiety disorder: a retrospective cohort study on therapeutic efficacy, gestational age and birth weight
Objective: To evaluate the efficacy of cognitive behavioral therapy in the treatment of generalized anxiety disorder during pregnancy and its effects on gestational age and birth weight. Methods: The sample included 28 untreated patients and 23 patients treated with CBT. Psychiatric diagnoses were determined through the Structured Clinical Interview for the DSM-IV. Symptom severity was assessed with standardized rating scales. Results: Post-treatment levels of anxiety symptoms were significantly lower than baseline. There was no significant difference in gestational age or newborn birth weight between the cognitive behavioral therapy group and the untreated group. Conclusions: Cognitive behavioral therapy appears to be a safe and effective treatment for generalized anxiety disorder during pregnancy.
- 1 February 2021
- Published by EDITORA SCIENTIFIC in Brazilian Journal of Psychiatry
- Vol. 43 (1) , 61-64
Open AccessCognitive-behavioral therapy in pregnant women with generalized anxiety disorder: a retrospective cohort study on therapeutic efficacy, gestational age and birth weight
Objective: To evaluate the efficacy of cognitive behavioral therapy in the treatment of generalized anxiety disorder during pregnancy and its effects on gestational age and birth weight. Methods: The sample included 28 untreated patients and 23 patients treated with CBT. Psychiatric diagnoses were determined through the Structured Clinical Interview for the DSM-IV. Symptom severity was assessed with standardized rating scales. Results: Post-treatment levels of anxiety symptoms were significantly lower than baseline. There was no significant difference in gestational age or newborn birth weight between the cognitive behavioral therapy group and the untreated group. Conclusions: Cognitive behavioral therapy appears to be a safe and effective treatment for generalized anxiety disorder during pregnancy.
- Open Access
- 23 October 2020
- Published by EDITORA SCIENTIFIC in Brazilian Journal of Psychiatry
- Vol. 43 (AHEAD) , 6-11
The course and clinical correlates of panic disorder during the postpartum period: a naturalistic observational study
Objective: To investigate the course of panic disorder and its demographic and clinical correlates during the postpartum period. Methods: Data were collected from 38 consecutive postpartum women diagnosed with panic disorder. Psychiatric assessments were carried out on the first day after delivery and at 6-8 weeks postpartum. During the first assessment, the Panic and Agoraphobia Scale (PAS), Hospital Anxiety and Depression Scale (HADS), Coping Orientation to Problems Experienced (COPE), Multidimensional Scale of Perceived Social Support (MSPSS), and Temperament Evaluation of Memphis, Pisa, Paris, and San Diego Autoquestionnaire (TEMPS-A) were administered to the participants. PAS was also administered at the second assessment. Results: The mean PAS score reduced significantly from baseline to the second assessment. Logistic regression analysis indicated that a shorter duration of panic disorder independently predicted a ≥ 50-point decrease in the severity of panic symptoms during the postpartum period. Conclusion: These findings suggest that patients with a short duration of illness may experience significant alleviation in the severity of panic symptoms during the postpartum period.
- 23 October 2020
- Published by EDITORA SCIENTIFIC in Brazilian Journal of Psychiatry
- Vol. 43 (AHEAD) , 6-11
Open AccessThe course and clinical correlates of panic disorder during the postpartum period: a naturalistic observational study
Objective: To investigate the course of panic disorder and its demographic and clinical correlates during the postpartum period. Methods: Data were collected from 38 consecutive postpartum women diagnosed with panic disorder. Psychiatric assessments were carried out on the first day after delivery and at 6-8 weeks postpartum. During the first assessment, the Panic and Agoraphobia Scale (PAS), Hospital Anxiety and Depression Scale (HADS), Coping Orientation to Problems Experienced (COPE), Multidimensional Scale of Perceived Social Support (MSPSS), and Temperament Evaluation of Memphis, Pisa, Paris, and San Diego Autoquestionnaire (TEMPS-A) were administered to the participants. PAS was also administered at the second assessment. Results: The mean PAS score reduced significantly from baseline to the second assessment. Logistic regression analysis indicated that a shorter duration of panic disorder independently predicted a ≥ 50-point decrease in the severity of panic symptoms during the postpartum period. Conclusion: These findings suggest that patients with a short duration of illness may experience significant alleviation in the severity of panic symptoms during the postpartum period.
- 28 September 2020
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 40 (6) , 615-617
Citalopram in Treatment of Pregnant Women With Panic Disorder
Purpose: The study aimed to investigate efficacy of citalopram in pregnant women with panic disorder. Methods: The study data with 22 patients were retrospectively collected from clinical registers. The study was conducted in patients with and without comorbid major depression. The patients were evaluated using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, the Clinical Global Impression-Improvement Scale, the Hamilton Depression Rating Scale, and the Hamilton Rating Scale for Anxiety. Findings: The Hamilton Depression Rating Scale and the Hamilton Rating Scale for Anxiety scores were significantly reduced after treatment with citalopram at 20 mg/d for 8 weeks. The response rate based on Clinical Global Impression-Improvement Scale was 68.2%. Patients with comorbid major depression seemed to have a lower response rate compared with nondepressed patients. Implications: The current study suggests that citalopram may be beneficial for in pregnant women with panic disorder.
- 28 September 2020
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 40 (6) , 615-617
Citalopram in Treatment of Pregnant Women With Panic Disorder
Purpose: The study aimed to investigate efficacy of citalopram in pregnant women with panic disorder. Methods: The study data with 22 patients were retrospectively collected from clinical registers. The study was conducted in patients with and without comorbid major depression. The patients were evaluated using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, the Clinical Global Impression-Improvement Scale, the Hamilton Depression Rating Scale, and the Hamilton Rating Scale for Anxiety. Findings: The Hamilton Depression Rating Scale and the Hamilton Rating Scale for Anxiety scores were significantly reduced after treatment with citalopram at 20 mg/d for 8 weeks. The response rate based on Clinical Global Impression-Improvement Scale was 68.2%. Patients with comorbid major depression seemed to have a lower response rate compared with nondepressed patients. Implications: The current study suggests that citalopram may be beneficial for in pregnant women with panic disorder.